He is currently an Associate Professor of Ophthalmology at Sidney Kimmel Medical College of Thomas Jefferson University and is actively involved in the education and training of the next generation of ophthalmologists and retina specialists.īoard-certified by the American Board of Ophthalmology since 2010, Dr. In 2013, he returned to Philadelphia and the Retina Service of Wills Eye Hospital. Chiang was in private practice in the San Francisco Bay Area as a retina surgeon and recognized as a Top Doctor by Oakland Magazine.
Prior to joining Mid Atlantic Retina, Dr. He then completed a two-year medical and surgical retina fellowship at Wills Eye Hospital in Philadelphia and was the recipient of the William Tasman, MD Outstanding Fellow Award.
At UCLA, his performance was dually recognized with the Stein Resident Awards for Surgical Excellence and Clinical Research. Thereafter, he completed a residency in ophthalmology at the prestigious Stein Eye Institute at the University of California at Los Angeles (UCLA), perennially the #1 eye hospital in the western US. He then completed a transitional internship at Scripps Mercy Hospital in San Diego, the oldest hospital and one of the best in that region. from the New York University School of Medicine with distinction and selection into the Alpha Omega Alpha Medical Honor Society. Allen Chiang graduated Magna Cum Laude from Brown University. Proprietary or commercial disclosures may be found after the references.Īge-related macular degeneration Brimonidine Geographic atrophy Implant Nonexudative.Ĭopyright © 2023 American Academy of Ophthalmology. The study was terminated early because of the lower-than-expected GA progression rate in the sham/control group. The primary efficacy endpoint at 24 months was not met, but there was a numeric trend for reduction in GA progression at 24 months compared with sham treatment. Multiple intravitreal administrations of Brimo DDS (Gen 2) were well tolerated. Treatment-related adverse events were usually related to the injection procedure. Exploratory analysis showed numerically smaller loss over time in retinal sensitivity assessed with scotopic microperimetry with Brimo DDS than with sham (P = 0.053 at month 24). At month 30, GA area change from baseline was 4.09 (0.15) mm 2 with Brimo DDS (n = 49) versus 4.52 (0.15) mm 2 with sham (n = 46), a reduction of 0.43 mm 2 (10%) with Brimo DDS compared with sham (P = 0.033). Least squares mean (standard error) GA area change from baseline at month 24 (primary endpoint) was 3.24 (0.13) mm 2 with Brimo DDS (n = 84) versus 3.48 (0.13) mm 2 with sham (n = 91), a reduction of 0.25 mm 2 (7%) with Brimo DDS compared with sham (P = 0.150). The study was terminated early, at the time of the planned interim analysis, because of a slow GA progression rate (∼ 1.6 mm 2/year) in the enrolled population. The primary efficacy endpoint was GA lesion area change from baseline in the study eye, assessed with fundus autofluorescence imaging, at month 24. Patients diagnosed with GA secondary to AMD and multifocal lesions with total area of > 1.25 mm 2 and ≤ 18 mm 2 in the study eye.Įnrolled patients were randomized to treatment with intravitreal injections of 400-μg Brimo DDS (n = 154) or sham procedure (n = 156) in the study eye every 3 months from day 1 to month 21. To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).Ī phase IIb, randomized, multicenter, double-masked, sham-controlled, 30-month study (BEACON).
1 Jacobs Retina Center, University of California San Diego, La Jolla, California.
0 kommentar(er)
